Lenalidomide Maintenance Post-debulking in Advanced CTCL
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Observation is watching a patient's condition but not giving treatment unless
symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood
flow to the cancer. It is not yet known whether observation or lenalidomide is more effective
in treating patients who are in complete or partial response after receiving previous
gemcitabine hydrochloride or doxorubicin hydrochloride liposome for cutaneous T-cell lymphoma
or mycosis fungoides/Sézary syndrome.
PURPOSE: This randomized phase III trial is studying observation to see how well it works
compared with lenalidomide in treating patients who are in complete or partial response after
receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for stage
IIB, stage III, or stage IV cutaneous T-cell lymphoma or stage IIB, stage III, or stage IV
mycosis fungoides/Sézary syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC